Sleeping Country Series 3. COVID-19 ARDS TREATMENT: Dapsone competes with SARS-CoV-2 Inflammasome.
INFOMEDPRESS, 2021. 8. 7.
The author has been studying mild cognitive impairment since 2008. The reason was that his mother was diagnosed. Furthermore, he found a cure, and his mother was healthy until 2018. By the way, she has been taking donepezil since 2016 because pharmaceuticals stopped producing her treatment medication. The author regretted not taking measures in 2016. To treat his mother's Alzheimer's disease, which has occurred since 2018, he has been inquiring all over the place. By importing the drug from Germany, he returned his mother's Alzheimer's disease to mild cognitive impairment. In 2020, his mother was diagnosed with pneumonia and then had a stroke. On January 3, 2021, she went to heaven. January 3, 2021, was when a respiratory specialist in the intensive care unit of Hunt Regional Hospital in Greenville, Texas, sent the results of the inflammasome clinical study he was studying. The results of the study were to validate a treatment for respiratory failure for COVID-19. The author's mother went face-to-face with the disease to leave one of the cures for COVID-19, and she gave everything to humans. The name of this treatment is the Soon Joe treatment.
다른 사람들의 의견 - 서평 쓰기
서평을 찾을 수 없습니다.
V Dapsone inhibits myeloperoxidase
VI Dapsone controls the mechanism of Sulfur in Radical Reactions and Peptide Aggregation
VII Dapsone binds to DNA but is transiently noncovalent
VIII Dapsone competes in the ubiquitination process
Specific Treatment Exists for SARSCoV2 ARDS
Supplementary material for
The Method and Results of a Treatment Targeting SARSCoV2Activated Inflammasomes
Commentary for the Elderly in the pandemic era
44Diaminodiphenyl Sulfone DDS as an Inflammasome Competitor
2 Materials and Methods
Preparation for Randomized Controlled Trial of dapsone for Covid19 ARDS
Letters for SARSCoV2 inflammasome
according acid activation acute addition administered Aging Alzheimer’s disease amyloid analysis ARDS ARDS onset associated binding brain caused cells changed chi-square chronic clinical cognitive competitor complex coronavirus dapsone death decreased Dementia diagnosed drug effects electron enzyme Figure FIO2 function gene Hansen’s human hypersensitivity hypoxia identified increased induced infection inflammation inflammatory influenza involvement Journal Korea leprosy methionine mild molecular myeloperoxidase NLRP3 inflammasome outcomes oxidation pandemic Park patients Pneumocystis carinii Pneumonia pneumonia potential prescribed prevent production progression properties protein radical randomized reactions receptor reduced Regional regulates reported requirement respiratory respiratory diseases response result risk role severe side effects signalling significant Sorok Island Sorokdo National Hospital South Korea stage standard started Statistical stop subjects sulfone symptoms syndrome Table taking Dapsone treat treatment trial ubiquitin unspecified viral virus